Organization · Venture Capital
Ysios Capital
Ysios Capital is a Spanish venture capital firm focused on early and mid-stage life science companies, particularly in biotechnology. With a strong emphasis on innovative therapeutic drugs, it manages over €400M across three dedicated funds.
Overview
What Ysios Capital does
What Ysios Capital is
Ysios Capital is a Spanish venture capital firm focused on early and mid-stage life science companies, particularly in biotechnology. With a strong emphasis on innovative therapeutic drugs, it manages over €400M across three dedicated funds.
How it participates in the startup ecosystem
The current public profile supports funder and event host and publisher capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2008
- Approximate age
- About 18 years
- Structured capabilities
- Funder · Event host · Publisher
- Last reviewed
- March 27, 2026
Official channels
Find Ysios Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Ysios Capital as a funder
Investment thesis
Ysios Capital focuses on investing in innovative biotech companies that develop novel therapies for high unmet medical needs, with a strong emphasis on late preclinical and early clinical projects.
Focus narrative
Ysios Capital invests globally in biotech ventures, concentrating on innovative therapeutic drugs. Their investment strategy encompasses both asset-centric companies and product-enabling platform technologies, primarily focusing on late preclinical and early clinical projects. The firm seeks to partner with exceptional teams that possess pioneering science and a commitment to transforming patient care.
Value beyond capital
Ysios Capital adds value to its portfolio companies by leveraging its extensive network in the biotech industry, providing strategic guidance, and facilitating partnerships with leading pharmaceutical companies. The firm also supports its companies in navigating the complex regulatory landscape and accessing funding for research and development.
Terms and economics
- Typical check
- $1,000,000–$10,000,000
- Sweet spot
- $5,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity
- Regions
- Europe · Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 33
- Recorded notable exits
- Tigenix, Biovex, STAT-Diagnostica, and Prexton
Portfolio context
Notable portfolio companies include: Adcendo (Denmark): Developing targeted anti-cancer therapies based on antibody-drug conjugates. AELIX Therapeutics (Spain): A clinical-stage company that developed a vaccine for HIV, acquired by Gilead Sciences. AM Pharma (Netherlands): Focused on developing alkaline phosphatase as a treatment for severe inflammatory diseases. Anaconda Biomed (Spain): Innovating in medical technology for ischemic stroke treatment. Aura Biosciences (USA): Developing therapies for ocular cancers. VarmX (Netherlands): Specializes in therapeutic proteins for bleeding prevention.
Capability profile
Ysios Capital as an event host
Event focus
Ysios Capital focuses on investing in innovative biotech ventures globally, particularly those developing novel therapies for high unmet medical needs. The firm seeks exceptional teams with pioneering science and a commitment to transforming patient care. Their investment strategy encompasses both asset-centric companies and product-enabling platform technologies, with a focus on late preclinical and early clinical projects.
Participant value
Ysios Capital provides significant funding and strategic support to biotech companies, helping them navigate the complexities of drug development and bringing innovative therapies to market. Their extensive experience and network in the biotech sector enhance the potential for portfolio companies to succeed.
Format and cadence
- Startups can present
- Yes
Availability
- Registration state
- Accepting
- Next recorded event
- March 3, 2026
- Next event location
- Amsterdam
Audience and fit
- Stages
- Pre-seed · Seed · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity
- Audience
- Founders · Investors
- Sectors
- Biotech & Life Sciences
- Regions
- Europe · Global
Capability profile
Ysios Capital as a publisher
Editorial focus
Ysios Capital is a European venture capital firm founded in 2008, specializing in investments in innovative biotech companies that develop novel therapies for high unmet medical needs. The firm targets late preclinical and early clinical projects, seeking exceptional teams with pioneering science to change patients' lives.
Audience value
Ysios Capital provides strategic investment in biotech ventures, focusing on innovative therapeutic drugs and supporting companies that aim to address significant medical challenges.
Format and cadence
- Content formats
- newsletter and research-report
Availability
- Guest pitch state
- Not currently accepting
Audience and focus
- Audience
- Investors · Founders
- Sectors
- Biotech & Life Sciences
- Regions
- Europe · Global
Flagship work and coverage
Flagship properties
Ysios Capital publishes newsletters and reports to communicate their investment strategies and portfolio updates.
Notable coverage
Ysios Capital has been recognized as Spain's largest life sciences VC, with a strong track record of backing globally competitive biotech companies and notable exits to top-tier pharma firms.
Common questions
What to know about Ysios Capital
Upseed classifies Ysios Capital under the Venture Capital organization type. Its current public profile includes funder, event host, and publisher capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 27, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.